Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; crospovidone; sodium carbonate; hyprolose; calcium stearate; hypromellose; titanium dioxide; iron oxide yellow; propylene glycol; triethyl citrate; purified talc; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion. duodenal ulcer. gastric ulcer. gastroesophageal reflux disease (gord). symptomatic gord: the treatment of heartburn and other symptoms associated with gord. reflux oesophagitis. gastrointestinal lesions refractory to h 2 -blockers. zollinger-ellison syndrome. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective nsaids in increased risk patients with a need for continuous nonselective nsaid treatment

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium delayed-release tablets, usp are indicated for: pantoprazole is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed‑release tablets is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. hyp

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - pantoprazole sodium sesquihydrate 45.1mg equivalent to pantoprazole base 40 mg - enteric coated tablet - 40 mg - active: pantoprazole sodium sesquihydrate 45.1mg equivalent to pantoprazole base 40 mg excipient: calcium stearate crospovidone hyprolose mannitol methacrylic acid - ethyl acrylate copolymer   opacode black s-1-17823 opadry yellow oy-52945 purified talc   sodium carbonate titanium dioxide triethyl citrate zein - 1. for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: · duodenal ulcer · gastric ulcer · gastro-oesophageal reflux disease (gord) - for the treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) - reflux oesophagitis · zollinger-ellison syndrome 2. eradication of helicobacter pylori (hereinafter referred to as h. pylori) in combination with · clarithromycin and amoxycillin or · clarithromycin and metronidazole or · amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism. 3. prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaid treatment.

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. - pantoprazole sodium delayed-release tablets are contraindic

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. - pantoprazole sodium delayed-release tablets are contraindic

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.4 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) duodenal ulcer; ii) gastric ulcer; iii) gastro-oesophageal reflux disease (gord): symptomatic gord. the treatment of heartburn and other symptoms associated with gord; reflux oesophagitis; iv) gastrointestinal lesions refractory h2 blockers; v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium delayed-release tablets, usp are indicated for: pantoprazole is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed‑release tablets is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. hyp

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium delayed-release tablets usp are indicated for: pantoprazole sodium delayed-release tablets usp are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets usp may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets usp are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets usp are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. pantoprazole sodium delayed-release tablets are contraindicated in patients with know